Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers

In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2015-03, Vol.101 (2), p.139-143
Main Authors: Rimassa, Lorenza, Santoro, Armando, Daniele, Bruno, Germano, Domenico, Gasbarrini, Antonio, Salvagni, Stefania, Masi, Gianluca, Abbadessa, Giovanni, Lamar, Maria, Goldberg, Terri, Porta, Camillo
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Female
Gene Expression Regulation, Neoplastic
Humans
Italy - epidemiology
Kaplan-Meier Estimate
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Male
Middle Aged
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - therapeutic use
Proto-Oncogene Proteins c-met - antagonists & inhibitors
Pyrrolidinones - pharmacology
Pyrrolidinones - therapeutic use
Quinolines - pharmacology
Quinolines - therapeutic use
Treatment Failure
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.
ISSN:0300-8916
2038-2529
DOI:10.5301/tj.5000217